Compare ADMA Biologics Inc (ADMA) vs OneSpan Inc (OSPN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs OneSpan Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while OneSpan Inc trades at $14.67 (market cap $559.43M). The key difference: ADMA Biologics Inc is far larger — about 3.8× OneSpan Inc's market cap, and OneSpan Inc pays a 3.45% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | OSPN | |
|---|---|---|
Market Cap | $2.13B | $559.43M |
Sector | Health | Technology |
52-Week High | $20.38 | $18.05 |
52-Week Low | $7.60 | $10.15 |
Enterprise Value | $2.20B | $517.63M |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
OneSpan (OSPN) trades at $15.09, up 4.5% today, showing strong momentum despite trading above the analyst consensus price target of $13.50. The stock exhibits bullish technical signals with recent earnings beats and robust profitability metrics including 28.5% net income margin and 27.8% ROE. Recent corporate developments include leadership team expansion and digital credentials launch, signaling growth initiatives.
The outlook remains positive with strong analyst support (67% buy ratings) and attractive valuation multiples (P/E 8.3x), though risks include negative cash flow trends and competitive pressures. Upside potential exists if the company maintains earnings momentum, while execution risks and market volatility present headwinds for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
